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Spinal muscular atrophy is a neurodegenerative disorder caused by the deletion or mutation of the survival-of-
motor-neuron gene, SMN1. An SMN1 paralog, SMN2, differs by a CrT transition in exon 7 that causes substantial
skipping of this exon, such that SMN2 expresses only low levels of functional protein. A better understanding of
SMN splicing mechanisms should facilitate the development of drugs that increase survival motor neuron (SMN)
protein levels by improving SMN2 exon 7 inclusion. In addition, exonic mutations that cause defective splicing
give rise to many genetic diseases, and the SMN1/2 system is a useful paradigm for understanding exon-identity
determinants and alternative-splicing mechanisms. Skipping of SMN2 exon 7 was previously attributed either to
the loss of an SF2/ASF–dependent exonic splicing enhancer or to the creation of an hnRNP A/B–dependent exonic
splicing silencer, as a result of the CrT transition. We report the extensive testing of the enhancer-loss and silencer-
gain models by mutagenesis, RNA interference, overexpression, RNA splicing, and RNA-protein interaction ex-
periments. Our results support the enhancer-loss model but also demonstrate that hnRNP A/B proteins antagonize
SF2/ASF–dependent ESE activity and promote exon 7 skipping by a mechanism that is independent of the CrT
transition and is, therefore, common to both SMN1 and SMN2. Our ﬁndings explain the basis of defective SMN2
splicing, illustrate the ﬁne balance between positive and negative determinants of exon identity and alternative
splicing, and underscore the importance of antagonistic splicing factors and exonic elements in a disease context.
Received September 1, 2005; accepted for publication October 7, 2005; electronically published November 16, 2005.
Address for correspondence and reprints: Dr. Adrian R. Krainer, Cold Spring Harbor Laboratory, P.O. Box 100, Cold Spring Harbor, NY
11724. E-mail: krainer@cshl.edu
* These two authors contributed equally to this work.
† Present afﬁliation: Memorial Sloan Kettering Cancer Center, Molecular Pharmacology and Chemistry, New York.
‡ Present afﬁliation: Department of Molecular and Medical Genetics, University of Toronto, Toronto.
Am. J. Hum. Genet. 2006;78:63–77.  2005 by The American Society of Human Genetics. All rights reserved. 0002-9297/2006/7801-0008$15.00
Spinal muscular atrophy (SMA types I, II, and III [MIMs
253300, 253550, and 253400]) is an autosomal reces-
sive neurodegenerative disease characterized by the se-
lective destruction of spinal cord a-motor neurons. SMA
is a leading genetic cause of infant mortality, with an
estimated incidence of 1 in 6,000–10,000 live births, and
is caused by the homozygous loss or mutation of the
SMN1 gene (Entrez Gene ID number 6606), which codes
for the survival motor neuron (SMN) protein (UniProt
accession number Q16637-1) (Lefebvre et al. 1995; re-
viewed by Frugier et al. [2002]). SMN is a ubiquitously
expressed, essential protein necessary for the efﬁcient
assembly of ribonucleoprotein complexes (reviewed by
Meister et al. [2002] and Gubitz et al. [2004]). SMN2
(Entrez Gene ID number 6607), a nearly identical para-
log of SMN1, is present in the human genome as part
of an inverted duplication on 5q13. SMN2 expresses
limited amounts of functional, full-length SMN protein,
which is apparently sufﬁcient for normal activity in most
cell types but not in motor neurons. SMN2 is efﬁciently
transcribed but cannot fully compensate for the loss of
SMN1, because a translationally silent, single-nucleotide
transition in SMN2 at position 6 of exon 7 (c6t) causes
predominant exon 7 skipping (Lefebvre et al. 1995; Lor-
son et al. 1999; Monani et al. 1999) and results in an
unstable protein (SMND7) (UniProt accession number
Q16637-3) with a different C-terminus (Lorson and An-
drophy 2000). Increased expression from SMN2 can re-
duce the severity of SMA, as seen when multiple copies
of SMN2 are present, both in patients and mouse models
(reviewed by Monani et al. [2000] and Frugier et al.
[2002]). Current efforts to develop therapeutics for SMA
are largely directed at increasing SMN2-derived full-
length SMN protein abundance or activity at the tran-
scriptional and posttranscriptional levels (Jarecki et al.
2005 and references therein), including approaches
aimed speciﬁcally at changing the ratio of the two main
splicing isoforms in favor of the full-length active one
(Lim and Hertel 2001; Miyajima et al. 2002; Cartegni
and Krainer 2003; Skordis et al. 2003).
Signals located within an exon can have positive or
negative effects on the recognition of that exon during
splicing. Exonic splicing enhancers (ESEs) stimulate
splicing and are often required for efﬁcient intron re-
moval, whereas exonic splicing silencers (ESSs) inhibit
splicing. ESSs and ESEs frequently antagonize each
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other—for example, in the context of alternative splicing
regulation (reviewed by Hastings and Krainer [2001]
and Ca´ceres and Kornblihtt [2002]). The speciﬁc se-
quence and location of these cis-elements determine the
proteins that mediate the splicing activity. Well-charac-
terized ESEs include those recognized by SR proteins, a
family of RNA-binding proteins with distinctive serine/
arginine–rich domains (reviewed by Ca´ceres and Korn-
blihtt [2002] and Cartegni et al. [2002]). Some ESSs are
recognized by hnRNP A1 (UniProt accession number
P09651-2), an abundant RNA-binding protein that
plays an important role in splicing repression (reviewed
by Ca´ceres and Kornblihtt [2002] and Dreyfuss et al.
[2002]). As exempliﬁed by SMA, point mutations that
alter splicing signals can cause a loss of normal gene
expression as a result of aberrant splicing. Indeed, ab-
errant splicing is a prevalent cause of genetic diseases
(reviewed by Ca´ceres and Kornblihtt [2002], Faustino
and Cooper [2003], and Pagani and Baralle [2004]).
Two different models have been proposed to explain
the observed difference in splicing between SMN1 and
SMN2: loss of an enhancer or gain of a silencer. The
ﬁrst model proposes the existence in SMN1 of an ESE
recognized by the SR protein SF2/ASF (UniProt acces-
sion number Q07955) (Cartegni and Krainer 2002). The
CrT transition in SMN2 disrupts this ESE and results
in exon 7 skipping. This transition eliminates a high-
score motif for SF2/ASF, according to ESEﬁnder, a pro-
gram that predicts ESEs that are responsive to one of
several SR proteins on the basis of experimental and
statistical analyses (Cartegni and Krainer 2002; Cartegni
et al. 2003). Mutational analysis, RNA-binding data,
transfection experiments, and in vitro splicing assays us-
ing extracts and recombinant proteins all supported a
direct role for SF2/ASF in SMN1 exon 7 inclusion that
is not maintained in SMN2 (Cartegni and Krainer 2002),
which is consistent with the notion that exon 7 skipping
in SMN2 transcripts results from the loss of the SF2/
ASF–dependent ESE. Furthermore, SMN2 splicing can
be corrected by targeting exon 7 with speciﬁc synthetic
effector molecules that mimic the function of SR proteins
(Cartegni and Krainer 2003) or with bifunctional mod-
iﬁed antisense oligonucleotides that comprise SF2/ASF–
binding sites (Skordis et al. 2003). The second model
asserts that, rather than eliminating an ESE, the pres-
ence of a T at position 6 of SMN2 exon 7 creates an
ESS that is recognized by hnRNP A1 and leads to in-
efﬁcient exon 7 inclusion (Kashima and Manley 2003).
Increased exon 7 inclusion following small interfering
RNA (siRNA)–mediated knockdown of hnRNP A1 and
the related protein hnRNP A2 (UniProt accession num-
ber P22626-2), as well as UV cross-linking assays, sug-
gested that hnRNP A1 inhibits SMN2 exon 7 inclusion,
whereas genetic depletion of SF2/ASF in the chicken cell
line DT-40 does not affect full-length SMN1 levels
(Kashima and Manley 2003). These two models are not
necessarily incompatible, since both the loss of an SF2/
ASF–speciﬁc ESE as well as the simultaneous creation
of an hnRNP A1–binding site could, in principle, be
contributing factors to SMN2 exon 7 skipping. Indeed,
these proteins are known to antagonize each other, a
competition that appears to be based on their relative
concentrations and RNA-binding properties (Mayeda
and Krainer 1992; Ca´ceres et al. 1994; Eperon et al.
2000; Zhu et al. 2001; reviewed by Black [2003]).
Because of the obvious implications for SMA, a clear-
er understanding of the mechanism of SMN1/SMN2
exon 7 splicing would signiﬁcantly impact the devel-
opment of therapeutic approaches. We have now rig-
orously tested the enhancer-loss and silencer-gain mod-
els, using extensive mutational analysis, RNA interfer-
ence (RNAi)–mediated knockdown, overexpression of
hnRNP A1 and SF2/ASF, in vivo and in vitro splicing
assays, and RNA-protein interaction analysis. We ﬁnd
that SMN2 exon 7 skipping primarily results from the
loss of the SF2/ASF–dependent ESE. Although hnRNP
A1 indeed has a strong inhibitory effect on exon 7 in-
clusion, this effect is independent of the CrT transition
and, therefore, is not speciﬁc to SMN2. The observed
antagonism between SF2/ASF and hnRNP A1 in the def-
inition of SMN1/2 exon 7, together with the variable
expression of these splicing regulators, may cause tissue-
speciﬁc differences in the extent of exon 7 inclusion and
thereby contribute to the motor neuron–restricted phe-
notype observed in SMA.
Material and Methods
RNA Afﬁnity Chromatography
RNA afﬁnity chromatography was performed with themod-
iﬁcation of a published technique (Caputi et al. 1999). RNA
oligonucleotides SMN.WT (5′-GGUUUCAGACAAAAUCA-3′)
and SMN.C6T (5′-GGUUUUAGACAAAAUCA-3′) were ob-
tained from Dharmacon. One hundred micrograms of each
RNA was oxidized with sodium m-periodate in a 24-ml re-
action. One hundred microliters (1:1 slurry) of adipic acid
dihydrazide agarose beads (Sigma) was mixed with the SMN1
or SMN2 RNA and was rotated overnight at 4C. A 250-ml
in vitro splicing reaction mix (Cartegni et al. 2002) including
100 ml of HeLa nuclear extract was added to 50 ml of the
SMN1 or SMN2 beads that were prewashed in buffer D with
0.1 M KCl, and the mixtures were incubated for 40 min at
30C. The beads were divided into three aliquots, which were
washed three times in buffer D with either 0.1 M KCl, 0.15
M KCl, or 0.2 M KCl. After the ﬁnal wash, the beads were
resuspended in 40 ml of protein sample buffer and were heated
at 90C for 10 min to elute the bound proteins. Ten microliters
of each protein sample was loaded on a 12% SDS polyacryl-
amide gel, which was then electroblotted onto a nitrocellu-
lose membrane and was probed with monoclonal antibodies
against hnRNP A1 or SF2/ASF (Hanamura et al. 1998).
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Figure 1 Mutational analysis of SMN exon 7 splicing. A, Radioactive RT-PCR analysis of RNA from SMN mutant minigenes expressed
in 293-HEK cells. Transcripts that either include or skip exon 7 are indicated. Check marks indicate the presence of a high-score SF2/ASF motif
(1.96), as predicted by ESEﬁnder 2.0 (Cartegni et al. 2003), or a 4 of 6 match to the hnRNP A1 consensus motif (Burd and Dreyfuss 1994).
Lane numbers correspond to the 30 minigene construct numbers listed in table 1. B, Results of multiple experiments (table 1) quantitated by
phosphorimage analysis and presented as scatterplots. The percentage of exon 7 inclusion was plotted against SF2/ASF ESEﬁnder 2.0 scores
(left) or against matches to the hnRNP A1 consensus binding motif (right). Thresholds are set at 1.96 for SF2/ASF, at between 3 and 4 matches
for hnRNP A1, and at 90% for exon inclusion. The white and black symbols represent SMN1 and SMN2, respectively. Quadrants where the
ESE-loss (left) and ESS-gain (right) models predict that the points should fall are shaded.
Minigene Construction, Transfections, and Expression
Analysis
All SMN constructs were derived from pCI-SMNx-wt (Car-
tegni et al. 2002), which is a derivative of pCITel (Lorson and
Androphy 2000). Mutations were introduced by site-directed
mutagenesis, with the use of a QuikChange kit (Stratagene).
Plasmids (1 mg) were transfected into 293-HEK cells by use of
FuGENE (Roche). For SF2/ASF overexpression experiments,
early-passage mouse embryo ﬁbroblasts (MEF) cells were co-
transfected with 2 mg of pCGT7-SF2/ASF and 400 ng of the
SMN minigene plasmids. Total RNA was isolated after 48 h
by use of Trizol (Life Technologies). Reverse transcription was
performed using 1 mg of DNase-treated total RNA, oligo(dT),
and Superscript II reverse transcriptase (Life Technologies).
Semiquantitative PCR was performed with the cDNA equiv-
alent of 10 ng of starting RNA, by use of AmpliTaq Gold
(Roche) and 30 ampliﬁcation cycles (94C for 30 s, 58C for
60 s, and 72C for 60 s) in reactions containing [a-32P]dCTP.
Primers were pCIFwdB (5′-GACTCACTATAGGCTAGCC-
TCG-3′) and SMN8-3005′R (5′-AAGTACTTACCTGAAA-
TCTAATCCACATTCAAATTTTCTCAACTG-3′). Products
were separated on 6% native polyacrylamide or 1% agarose
gels. The ﬁgures show either autoradiograms or ethidium bro-
mide–stained gels, but, in all cases, the quantitation of splicing
was based on phosphorimage analysis (Fujix BAS2000). The
relative abundance of each product was calculated after ad-
justment for differences in base composition. For the statistical
analysis in ﬁgure 1 and table 1, each mutant was tested in two
to four separate transfections. Correlation coefﬁcients were
calculated with the use of nonparametric Spearman rank cor-
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Table 1
Summary of SMN Exon 7 Mutations and Levels of Exon Inclusion
Minigene
Number Minigenea Sequenceb
SF2/ASF
Scorec
hnRNP A1
Scored
% (SD)
Includede
1 SMN1 GGTTTCAGACAAAATCA 3.77 3 98  3
2 SMN2 (c6t) GGTTTTAGACAAAATCA .81 4 1  2
3 SMN.cX6 GGTTTCcccCcAAATCA 1.29 1 88  5
4 SMN.tX6 GGTTTTtttttAAATCA 3.77 2 0  0
5 SMN.aX6 GGTTTaAaAaAAAATCA 3.33 3 6  7
6 SMN.gX6 GGTTTggGgggAAATCA .81 4 3  3
7 SMN1.t3 GGTTTCAGtttAAATCA .56 3 6  3
8 SMN1.t4 GGTTTCAttCttAATCA .65 2 26  15
9 SMN1.10g11g GGTTTCAGAggAAATCA 5.74 4 100  0
10 SMN2.10g11g GGTTTTAGAggAAATCA 2.79 4 93  5
11 SMN1.9g10g GGTTTCAGggAAAATCA 1.19 5 92  2
12 SMN2.9g10g GGTTTTAGggAAAATCA .78 6 4  5
13 SMN1.9t10g GGTTTCAGtgAAAATCA .71 4 99  1
14 SMN2.9t10g GGTTTTAGtgAAAATCA 1.46 5 10  2
15 SMN1.insCA GGTTTcaCAGACAAAATCA 3.77 3 100  1
16 SMN2.insCA GGTTTcaTAGACAAAATCA .81 4 59  5
17 SMN1.insCA9g10a GGTTTcaCAGgaAAAATCA 5.98 4 100  0
18 SMN2.insCA9g10a GGTTTcaTAGgaAAAATCA 3.67 5 98  2
19 SMN1.11g GGTTTCAGACgAAATCA 6.34 2 100  0
20 SMN2.11g GGTTTTAGACgAAATCA 3.39 3 96  2
21 SMN.6a11g GGTTTaAGACgAAATCA 3.84 3 100  0
22 SMN.6g11g GGTTTgAGACgAAATCA 4.77 4 100  1
23 SMN.6a GGTTTaAGACAAAATCA 1.26 3 72  2
24 SMN.6g GGTTTgAGACAAAATCA 2.19 3 99  1
25 SMN1.7c GGTTTCcGACAAAATCA 2.04 2 100  0
26 SMN2.7c GGTTTTcGACAAAATCA .09 3 100  0
27 SMN1.8c GGTTTCAcACAAAATCA 4.01 2 97  2
28 SMN2.8c GGTTTTAcACAAAATCA 1.49 3 57  3
29 SMN.BRCA.WT GGTTTCtGAgttAATCA 2.14 3 56  3
30 SMN.BRCA.Mut GGTTTCttAgttAATCA .08 4 0  0
a The 30 minigenes used in transfection experiments, in the same order as the lanes in ﬁgure 1A.
b Nucleotide sequence around the ESE/ESS motifs. The ESEﬁnder 2.0 SF2/ASF top-scoring motif for each
sequence is shown in bold italic type (if 10). The best ﬁt to the hnRNP A1–binding consensus (TAGGGA/
T) is underlined. SMN1 constructs have a T, and SMN2 constructs a C, at position 6. Mutations are
indicated in lowercase.
c Top SF2/ASF score. High-score motifs are shown in bold italic type (threshold p 1.96).
d Number of nucleotide matches to the hnRNP A1 hexamer consensus, shown in bold italic type when
13.
e Average inclusion percentages and SDs (n p 2–4) measured after radioactive RT-PCR in the linear
range.
relation and a bootstrap technique to determine the CIs. Ad-
ditional experiments using fewer PCR ampliﬁcation cycles gave
similar results.
For analysis of endogenous SMN splicing, 293-HEK cells
were transfected with 2 mg of pCGT7-A1 expression plasmid
(Ca´ceres et al. 1994). RT-PCR of total RNA was performed
as described above, with primers SMNex6FXho (5′-CG-
ATCTCGAGATAATTCCCCCACCACCTCCC-3 ′) and
SMNex8RNot (5′-ATATGCGGCCGCCACATACGCCTCAC-
ATACA-3′). Products were puriﬁed using PCR puriﬁcation col-
umns (Qiagen), were digested with DdeI, and were separated
on 6% native polyacrylamide gels. Protein lysates were col-
lected with Trizol and were analyzed by western blotting with
an anti-T7-Tag antibody (Novagen) and mAb 4G3 (Habets et
al. 1989) against human U2B′′ snRNP protein.
RNA Interference
Twenty-four hours before transfection of siRNAs with Oli-
gofectamine (Invitrogen), HeLa cells were seeded42.5# 10
into 24-well plates. After 24 h, SMN minigenes were trans-
fected using FuGENE, and the cells were incubated for another
24 h and then harvested for RNA isolation and western blot-
ting. The following siRNAs were used: hnRNPA1, 5′-CAGCU-
GAGGAAGCUCUUCA-3′; hnRNP A2, 5′-GGAACAGUUC-
CGUAAGCUC-3′; SF2/ASF, 5′-ACGAUUGCCGCAUCUA-
CGU-3′; and luciferase control, 5′-GCCAUUCUAUCCUCUA-
GAGGAUG-3′. RT-PCR was performed as described above.
Western blotting was performed using antibodies speciﬁc for
a-tubulin (Sigma B512) and for hnRNP A1 (4B10) and hnRNP
A2 (DP3B3), which were kindly provided by Gideon Dreyfuss.
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Figure 2 Binding speciﬁcity of SF2/ASF and hnRNPA1.Western
blot of proteins recovered from agarose beads covalently linked to
RNAs corresponding to the ﬁrst 17 nt of SMN1 or SMN2. The RNA
beads were incubated with identical aliquots of HeLa cell nuclear
extract under splicing conditions; they were then divided into three
aliquots for washing at the indicated salt concentrations, and the pro-
teins that remained bound were recovered by heating in SDS-sample
buffer. Blots were probed with monoclonal antibodies against SF2/ASF
(top) or hnRNP A1 (bottom). Supernatant (sup) and bound samples
shown correspond to 1/100th and 1/16th of the initial binding reac-
tions, respectively.
Nuclear Extract Depletion and in Vitro Splicing Analysis
HeLa cell nuclear extract was afﬁnity depleted of hnRNP
A/B proteins, as described elsewhere (Zhu et al. 2001). Three
microliters of mock-depleted or hnRNP A/B–depleted extract
was used in a standard reaction for SMN in vitro splicing
(Cartegni and Krainer 2002). Extracts were complemented
with recombinant hnRNP A1 protein, which was overexpres-
sed in Escherichia coli and was puriﬁed as described elsewhere
(Mayeda and Krainer 1992).
Results
SF2/ASF and hnRNP A1 Binding to SMN1 versus
SMN2 RNA
We previously used site-speciﬁc labeling to show the
preferential binding of SF2/ASF to exon 7 RNA from
SMN1 compared with SMN2 (Cartegni and Krainer
2002). Preferential binding of hnRNP A1 to SMN2 exon
7 RNA was shown by the uniform labeling of a 5′ frag-
ment of the exon (Kashima and Manley 2003). These
two observations were obtained using somewhat differ-
ent methodologies and are, therefore, not directly com-
parable, but both results relied on immunoprecipitation
after UV-induced cross-linking of radiolabeled RNAs to
proteins in nuclear extract. Biases can arise because dif-
ferent nucleotides cross-link to proteins with signiﬁ-
cantly different efﬁciencies. In particular, rU generally
cross-links more efﬁciently than does rC (Hockensmith
et al. 1991). SMN2 exon 7 RNA has a U at position
6 and would, therefore, be expected to cross-linkmore
efﬁciently to a bound protein than would SMN1, which
has a C at the same position. This difference in cross-
linking efﬁciency could account for the apparent differ-
ence in hnRNP A1 binding to SMN1 and SMN2 RNAs
(Kashima and Manley 2003). Conversely, this difference
in cross-linking efﬁciency could have resulted in an un-
derestimate of the preferential binding of SF2/ASF to the
region around position9 of SMN1, as noted elsewhere
(Cartegni and Krainer 2002).
To obtain a more direct and unbiased assessment of
proteins that bind to the RNA encompassing the CrT
transition, we performed RNA afﬁnity chromatography.
The ﬁrst 17 nt of SMN1 or SMN2 exon 7 RNA were
covalently linked to agarose beads via the 3′ end and
were incubated with HeLa cell nuclear extract. Proteins
that remained tightly bound to each RNA after washing
at different salt concentrations were analyzed using
monoclonal antibodies speciﬁc for hnRNP A1 or SF2/
ASF. hnRNP A1 bound efﬁciently to SMN1 and SMN2
RNA fragments with approximately equal efﬁciency (ﬁg.
2, bottom). In fact, incubation of nuclear extract with
either RNA resulted in the efﬁcient depletion of hnRNP
A1 from the extract, as evident in the supernatant frac-
tions. In contrast, SF2/ASF bound very speciﬁcally to the
SMN1 RNA fragment (ﬁg. 2, top), with minimal binding
to the corresponding SMN2 RNA, which is consistent
with the notion that the CrT transition results in the
loss of an SF2/ASF–dependent ESE. Although this ex-
perimental approach does not reveal the stoichiometry
or the precise location of the bound proteins along the
immobilized RNA probes, it is unlikely that more than
one or two molecules of SF2/ASF or hnRNP A1 can
bind to a 17mer RNA, given the available information
about their heptamer and hexamer recognition motifs
(Burd and Dreyfuss 1994; Cartegni et al. 2003), as well
as previous structural data (Ding et al. 1999; Maris et
al. 2005).
Extensive Mutational Analysis of SMN1 Exon 7
To assess the relationship between hnRNP A1 motifs
and exon skipping versus SF2/ASF motifs and exon in-
clusion, we designed a large panel of SMN minigenes
with different mutations surrounding the6 position of
exon 7 (table 1). We used ESEﬁnder 2.0 (Cartegni et al.
2003) to calculate SF2/ASF–dependent ESE motif scores
and used the consensus motif derived from SELEX (Burd
and Dreyfuss 1994) to assign putative hnRNP A1–bind-
ing sites. We transfected the constructs into 293-HEK
cells and measured the extent of exon 7 inclusion in the
spliced transcripts. The minigene constructs (minigenes
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1–30) are listed in table 1 in the same order as the 30
lanes in ﬁgure 1.
In the design of the ﬁrst set of mutants, we reasoned
that the gain of an element should be sequence speciﬁc,
requiring particular nucleotides that match the consen-
sus binding motif. In contrast, the loss of an element
should not require highly speciﬁc sequence changes as
long as the element is destroyed. We initially substitu-
ted 6 nt of the presumptive splicing elements with cyto-
sines (minigene 3: SMN.cX6), thymidines (minigene 4:
SMN.tX6), adenosines (minigene 5: SMN.aX6), or
guanosines (minigene 6: SMN.gX6) (table 1). Three of
these four mutations caused loss of exon 7 inclusion to
levels similar to SMN2 (c6t) (ﬁg. 1, lanes 4–6). The
SMN.cX6 mutation was an exception (see below), since
it only reduced inclusion by ∼15% (ﬁg. 1, lane 3). Sub-
stitution with a more limited number of thymidines
(minigene 7: SMN1.t3 and minigene 8: SMN1.t4) in the
putative enhancer element, while maintaining the C at
position 6, also led to very signiﬁcant exon skipping
(table 1 and ﬁg. 1, lanes 7 and 8). These two mutants
are equivalent to ones ﬁrst used to identify the sequences
surrounding position6 as being important for efﬁcient
SMN1 exon 7 inclusion (Lorson and Androphy 2000).
The ability to cause exon 7 skipping in such a nonspeciﬁc
manner strongly suggests that the mutations disrupt a
positively acting splicing element (i.e., an ESE) required
for SMN1 exon 7 inclusion.
To assess the involvement of hnRNP A1 in exon 7
splicing, we next tested whether mutations that
strengthen or weaken hnRNP A1–binding motifs cor-
relate with the extent of exon 7 skipping. SMN1 and
SMN2 have three and four nucleotide matches, respec-
tively, to the optimal hnRNP A1–binding hexamer, TA-
GGGA/T (Burd and Dreyfuss 1994). We tested three
pairs of SMN1/SMN2 minigenes with double mutations
at positions 9 to 11 (10g11g, 9g10g, and 9t10g)
combined with C or T at position 6 (minigenes 9–14,
table 1 and ﬁg. 1). Despite having at least the same
number of matches to the consensus hnRNP A1 motif
as SMN2, all but two of the mutations resulted in in-
creased exon 7 inclusion, showing that the introduction
of an hnRNP A1–binding motif does not consistently
result in exon 7 skipping. In the remaining two cases, a
perfect or near-perfect match at that site (i.e., minigene
12: SMN2.9g10g and minigene 14: SMN2.9t10g) was
indeed associated with exon skipping, but because these
mutations also simultaneously eliminate the SF2/ASF
high-score motif, the cause of exon skipping cannot be
unequivocally assigned (table 1 and ﬁg. 1, lanes 12 and
14).
The presence of UAG at the 5′ end of the hnRNP A1
consensus motif appears to be important for hnRNP A1
binding and silencing activity in other contexts (Burd
and Dreyfuss 1994; Caputi et al. 1999). To further eval-
uate whether the presence of an hnRNP A1–binding site
correlates with SMN2 exon 7 skipping, we tested two
sets of mutations (minigenes 25–28), 7c and 8c, that
target the UAG/CAG motif in SMN1 and SMN2 and
are equivalent to previously tested mutations (Kashima
and Manley 2003). Both SMN1.7c and SMN1.8c main-
tain a high-score SF2/ASF motif and, as predicted by the
ESE-loss model, gave high levels of exon 7 inclusion (ﬁg.
1, lanes 25 and 27). SMN2.7c lacks both a high-score
SF2/ASF motif and an hnRNP A1–binding motif but
maintained a high level of exon 7 inclusion (lane 26).
In SMN2.8c, the SF2/ASF motif was also eliminated,
correlating with the ∼50% exon 7 skipping despite the
absence of the UAG motif (lane 28). Indeed, when a
UAG motif was present without the concomitant dis-
ruption of the ESE (lanes 10, 18, and 20), exon 7 in-
clusion was close to 100%, pointing to a marginal role
of the UAG motif in this context.
Several mutants have good matches to both SF2/ASF
and hnRNP A1 motifs (table 1, minigenes 9, 10, 17, 18,
and 22) and gave high levels of exon 7 inclusion (ﬁg.
1), suggesting that the SF2/ASF high-score motif is the
functional or dominant element in determining exon 7
splicing. Two of these mutants are part of a set specif-
ically designed to test this hypothesis, by inserting a CA
dinucleotide upstream of the 6 C or T in SMN1 or
SMN2, respectively (table 1, minigenes 15 and 16). The
insertion, which leaves the preexisting SF2/ASF and
hnRNP A1 putative sites unaltered, maintained the high
level of exon 7 inclusion for SMN1 and partially im-
proved it for SMN2 (ﬁg. 1A, lanes 15 and 16). When
combined with a 9g10a mutation in the context of
SMN2 (table 1, minigene 18), the CA dinucleotide in-
sertion restores a high-score SF2/ASF motif and simul-
taneously strengthens the hnRNP A1–binding motif. De-
spite the strengthened hnRNPA1motif, exon 7 inclusion
increased to nearly 100% (ﬁg. 1, lane 18), indicating
that the presence of an hnRNP A1 motif at that position
contributes minimally to the levels of exon 7 skipping,
whereas an SF2/ASF motif appears to be a strong de-
terminant of inclusion.
Eight mutations had neither SF2/ASF motifs nor
hnRNP A1 motifs (table 1, minigenes 3–5, 7, 8, 23, 26,
and 28). Six of these eight mutations gave signiﬁcant
exon 7 skipping, consistent with the lack of the ESE
motif (ﬁg. 1, lanes 4, 5, 7, 8, 23, and 28). The other
two mutations, SMN2.7c and, to a lesser degree,
SMN.cX6, gave levels of exon 7 inclusion comparable
to SMN1 (lanes 3 and 26). Given that exon 7 inclusion
for the other mutations does not correlate with the lack
of an hnRNP A1–binding site, we infer that 7c and cX6
may fortuitously introduce an unrelated protein-binding
site and/or affect RNA secondary structure in a way that
facilitates splicing.
We also tested an SF2/ASF–dependent ESE found in
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BRCA1 exon 18, which is abrogated by a point muta-
tion that causes skipping of the exon (Liu et al. 2001).
In the context of the SMN minigene, the heterologous
BRCA1 ESE stimulated exon 7 inclusion above SMN2
levels, whereas complete exon skipping was observed
with the mutant version (table 1, minigenes 29 and 30,
and ﬁg. 1). Together with the reciprocal ﬁnding that the
SMN1 SF2/ASF ESE, but not the SMN2 version, can
replace the BRCA1 ESE (Cartegni and Krainer 2002),
this result shows that different SF2/ASF ESE heptamers
are functionally interchangeable.
Our ESE-loss model takes into account mutations that
were tested in previous studies (Lorson and Androphy
2000; Cartegni and Krainer 2002; Kashima and Man-
ley 2003) and that were also included in the present
study to conﬁrm previous results and to comprehensively
reassess the roles of SF2/ASF and hnRNP A1. For ex-
ample, one set of mutants (table 1, minigenes 19–24)
was originally designed to eliminate the SF2/ASF–de-
pendent ESE by introducing changes at position6 and,
then, to restore it by means of a compensatory mutation,
a11g (Cartegni and Krainer 2002). In agreement with
our previous observations, exon 7 inclusion was rescued
(ﬁg. 1, lanes 19–24). Two constructs, however, gave sig-
niﬁcantly different results compared with a previous re-
port (Kashima and Manley 2003). In that study, SMN2-
TG and SMN2-8C rescued SMN2 exon 7 inclusion to
levels similar to SMN1. Our equivalent constructs,
SMN2.9t10g and SMN2.8c, gave only 13% and 56%
exon inclusion, respectively (table 1, minigenes 14 and
28, and ﬁg. 1A), consistent with the reduction in the
SF2/ASF motif scores (see the “Discussion” section).
It is apparent from the above results that not every
mutant analyzed is consistent with the presence or ab-
sence of either an SF2/ASF or an hnRNP A1 motif. This
is to be expected, because any point mutation can po-
tentially create or destroy additional regulatory ele-
ments. However, the contribution of a particular motif
to the recognition of exon 7 can be assessed by the extent
of correlation between splicing and motif scores when
the entire panel of mutants is analyzed. We, therefore,
compiled the results from all of the mutations (table 1)
into a data set presented as scatterplots (ﬁg. 1B). The
graphs show the relationship between exon 7 inclusion
and either ESEﬁnder SF2/ASF motif scores (Cartegni et
al. 2003) or matches to the hnRNP A1–binding site con-
sensus (Burd and Dreyfuss 1994). The threshold for the
hnRNP A1–binding motifs is set at more than three
matches, because the transition from three matches in
SMN1 to four matches in SMN2 was proposed to be
the determinant of SMN2 exon 7 skipping (Kashima and
Manley 2003). To set a high threshold for ESE activity,
the extent of exon 7 inclusion considered indicative of
high inclusion was set at 90%. According to the ESE-
loss model, the data points should be distributed in the
lower left and upper right quadrants, which was indeed
the case for 26 of the 30 experimental points (ﬁg. 1B).
Moreover, there is a strong correlation between SF2/ASF
scores and exon 7 inclusion (Spearman rank correlation
coefﬁcient 0.75; 95% CI 0.53–0.88; perfect correlation
p 1) but not between hnRNP A1–binding motifs and
exon 7 skipping (correlation coefﬁcient 0.14; 95% CI
0.48 to 0.25; perfect correlation p 1). Indeed, the
ESS-gain model predicts that the data points should be
distributed in the lower right and upper left quadrants,
but, instead, the distribution appears to be random (ﬁg.
1B).
One caveat of this statistical analysis is that the SF2/
ASF and hnRNP A1 motifs were originally derived by
different methods, and they have different extents of
degeneracy. To allow an unbiased comparison of the
correlation between exon 7 inclusion and the twomotifs,
we derived a position weight matrix for hnRNP A1 from
the original SELEX data (Burd and Dreyfuss 1994), us-
ing the same methodology as originally employed for
the derivation of the SF2/ASF motif (Liu et al. 1998).
The new hnRNP A1 matrix and the statistical analysis
of the data are presented in appendix A (online only)
and gave results consistent with the match/mismatch ap-
proach. Once again, there was no correlation between
hnRNP A1 motif scores and the extent of exon 7 skip-
ping (ﬁgs. A1 and A2 [online only]). Taken together,
these results strongly suggest that the presence of an SF2/
ASF motif is important for exon 7 inclusion, whereas
an hnRNP A1 motif is neither necessary nor sufﬁcient
to promote exon 7 skipping.
Effects of Depletion and Overexpression on SMN
Splicing in Vivo
We have conﬁrmed and extended previous work that
demonstrated that simultaneous siRNA-mediated
knockdown of hnRNP A1 and a closely related hnRNP
A/B family member, hnRNP A2, signiﬁcantly increases
SMN2 exon 7 inclusion in HeLa cells (Kashima and
Manley 2003) (ﬁg. 3A and 3C). The original interpre-
tation of these results was that hnRNP A1/A2 inhibits
splicing of SMN2 exon 7 via an ESS introduced into
SMN2 by the CrT transition. Although this is a formal
possibility, we wished to address the speciﬁcity of the
hnRNP A1/A2 effect and an alternative interpretation—
namely, that nonspeciﬁc binding by hnRNP A1/A2 (or
speciﬁc binding elsewhere) becomes inhibitory in the ab-
sence of the SF2/ASF–dependent ESE.
If the observed hnRNP A1/A2 inhibitory activity is
general, rather than speciﬁc, it should repress exon 7
inclusion irrespective of the CrT transition. We, there-
fore, designed a mutation that weakens exon 7 inclusion
in SMN1 without affecting the region of the SF2/ASF–
dependent ESE. The mutation is a CrG transversion
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Figure 3 Analysis showing that depletion of hnRNP A1/A2 in vivo relieves exon 7 skipping, irrespective of the CrT transition. A, HeLa
cells were treated with siRNAs against hnRNP A1, A2, or both and then were transfected with SMN minigene plasmids. Endogenous levels of
hnRNP A1 and A2 and tubulin control were measured by western blotting 24 h after transfection (upper images). Radioactive RT-PCR analysis
was performed, and spliced products were visualized by ethidium-bromide staining (lower images). B, Sequences of the relevant portions of
intron 6 (lowercase) and exon 7 (uppercase) in the minigenes. Mutations are underlined, and the 8 and 6 positions are boxed. C, RT-PCR
products shown in panel A were quantitated on a phosphorimager. Note that the SMN1.t3 and SMN1.t4 mutants gave higher levels of inclusion
in HeLa cells than in 293-HEK cells (compare with ﬁg. 1A and table 1). D, Overexpression of SF2/ASF promotes exon 7 inclusion in SMN1.PyD.
MEF cells were cotransfected with an SF2/ASF expression plasmid or vector alone (C, lane 1) and the indicated SMN minigenes. RT-PCR
analysis and quantitation were performed as in panels A and C.
within the polypyrimidine tract of intron 6 (SMN1.PyD)
(ﬁg. 3B). This mutation weakens the 3′ splice site and
decreases exon 7 inclusion by 150% (ﬁg. 3A). If hnRNP
A1–mediated repression is indeed dependent on the T
at position 6, there should be no effect of hnRNP A1/
A2 depletion on splicing of this minigene, because the
C was retained and no ESS was introduced. However,
hnRNP A1/A2 depletion resulted in an approximately
twofold increase in exon 7 splicing with this mutant
(SMN1.PyD) (ﬁg. 3A, lanes 1–4, and ﬁg. 3C).
We next analyzed two additional mutations, SMN1.t3
and SMN1.t4, which have a C at position 6 of exon
7 but have neither SF2/ASF nor hnRNP A1 motifs (table
1). As predicted by the ESE-loss model, exon 7 inclusion
levels were low with both mutants. Upon hnRNP A1
and A2 depletion, however, inclusion increased approx-
imately twofold (ﬁg. 3A and 3C), supporting the con-
clusion that the hnRNPA/B–mediated inhibition of exon
7 inclusion is an indirect effect, independent of the CrT
transition in SMN2 and consistent with the general in-
hibitory properties of hnRNP A/B proteins (Mayeda et
al. 1993; Cartegni et al. 2002; Black 2003).
The SMN1.PyD mutant splices at suboptimal levels
but, at the same time, maintains an intact, responsive
ESE and, therefore, can be used to test whether SF2/ASF
can promote exon 7 inclusion in cells. We overexpressed
SF2/ASF in MEF cells, which have low basal levels of
endogenous SF2/ASF, compared with transformed cell
lines. As expected, there was no signiﬁcant improvement
in splicing with the SMN1 and SMN2 minigenes, since
SMN1 exon 7 inclusion is already very efﬁcient and
SMN2 lacks the SF2/ASF motif (ﬁg. 3D). In contrast,
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Figure 4 Analysis showing that overexpression of hnRNP A1
in vivo inhibits SMN1 and SMN2 exon 7 inclusion. Top, Radioactive
RT-PCR analysis was performed with RNA from control mock-trans-
fected 293-HEK cells (C, lane 1) or cells expressing T7-tagged hnRNP
A1 (lane 2). To distinguish between SMN1 and SMN2 endogenous
mRNAs, the cDNAs were digested with DdeI to speciﬁcally cleave
SMN2 in exon 8. Products were separated on a 6% native polyacryl-
amide gel. The white box represents the 3′ end of exon 8 that was
cleaved from SMN2 spliced products. The proportion of SMN1 and
SMN2 transcripts lacking exon 7 (% skip) is shown below the au-
toradiogram. Bottom, Western blot of lysates from mock-transfected
cells or cells expressing T7-tagged hnRNP A1. Blots were probed with
anti-T7 antibody and an antibody against U2B′′ as a control.
the level of exon 7 inclusion from the SMN1.PyDmutant
increased about twofold, indicating that the ESE is re-
sponsive to varying levels of SF2/ASF in vivo.
If hnRNP A1 speciﬁcally inhibits exon 7 inclusion in
SMN2, then hnRNP A1 overexpression would be ex-
pected to inhibit inclusion even further, whereas SMN1
should not be affected. In contrast, if hnRNP A1–me-
diated inhibition is a global and/or nonspeciﬁc effect,
its overexpression should also cause an increase in
SMN1 exon 7 skipping. To determine which prediction
is correct, we transiently overexpressed hnRNP A1 in
293-HEK cells and analyzed the splicing of RNA tran-
scripts from the endogenous SMN1 and SMN2 genes.
The endogenous SMN2 gene can be distinguished from
SMN1 by a GrA transition in the 3′ UTR in exon 8
that creates a DdeI site (Gennarelli et al. 1995; Parsons
et al. 1996). Analysis ofDdeI-digestedRT-PCR reactions
showed that the SMN1 cDNAs from control cells cor-
respond to essentially 100% inclusion of exon 7 (ﬁg. 4,
lane 1). In contrast, overexpression of hnRNP A1 re-
sulted in the appearance of SMN1 transcripts lacking
exon 7 (lane 2), indicating that hnRNP A1 can inhibit
endogenous SMN1 exon 7 splicing. An increase in exon
7 skipping was also observed for the SMN2 transcripts.
Inhibition of SMN1 and SMN2 Exon 7 Splicing by
hnRNP A1 in Vitro
The role of hnRNP A1 in SMN1 and SMN2 exon 7
splicing can be tested directly with the use of an in vitro
splicing assay (Cartegni and Krainer 2002). SMN1 exon
7 inclusion is less efﬁcient in vitro than in vivo, facili-
tating the detection of changes that lead to increased
exon inclusion. Indeed, depletion of hnRNPA/B proteins
from nuclear extracts (ﬁg. 5A) resulted in a signiﬁcant
increase in SMN1 exon 7 inclusion, relative to mock-
depleted extracts (ﬁg. 5B, lanes 1 and 4). This effect was
even greater than that on SMN2 (ﬁg. 5B, lanes 7 and
10). The addition of recombinant hnRNP A1 resulted
in dose-dependent inhibition of both SMN1 and SMN2
exon 7 inclusion (ﬁg. 5B, lanes 4–6 and 10–12). Because
SMN1 exon 7 inclusion was also inhibited, these results
further demonstrate that the hnRNP A1–mediated effect
is independent of the CrT transition in SMN2.
Discussion
The SMN2 gene can potentially express sufﬁcient func-
tional SMN protein to fully compensate for the loss of
SMN1 in all patients with SMA, which makes it an at-
tractive target for drug therapy. The development of
therapeutic approaches would be greatly facilitated by
precise knowledge of the mechanism by which SMN2
exon 7 fails to be efﬁciently incorporated into mature
transcripts. The identiﬁcation of the cis-elements and
trans-acting factors involved is essential for the opti-
mization of current approaches and/or for the identiﬁ-
cation of new drug targets. Two different models, which
are not necessarily incompatible, were previously pro-
posed to explain the different splicing patterns of SMN1
and SMN2: loss of an SF2/ASF–dependent enhancer in
SMN1 (Cartegni and Krainer 2002) or gain of an
hnRNP A1–dependent silencer in SMN2 (Kashima and
Manley 2003). We have now systematically assessed the
roles of hnRNP A1 and SF2/ASF in SMN1/2 exon 7
splicing and conclude that the primary determinant of
the extent of exon 7 inclusion is the SF2/ASF–dependent
ESE. Interestingly, hnRNP A1 can antagonize SF2/ASF
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Figure 5 Analysis showing that hnRNP A1 inhibits SMN1 and
SMN2 exon 7 splicing in vitro. A, Western blot of hnRNP A1 in 1 ml
of HeLa nuclear extract (NE), mock-depleted extract (m), extract de-
pleted of hnRNP A/B proteins (DA1), and 50 ng of recombinant
hnRNP A1 (rA1). B, In vitro splicing of SMN1 and SMN2 transcripts
in 3 ml of mock- or hnRNP A/B–depleted extract supplemented with
0 (), 170, or 340 ng of recombinant hnRNP A1. Marker lane is
indicated (M).
and, indeed, promote exon 7 skipping. However, this
activity of hnRNP A1 is not speciﬁc to SMN2 but rather
reﬂects the general inhibitory effect of hnRNP A1 on
many alternatively spliced exons (reviewed in Cartegni
et al. 2002), illustrating the antagonism between these
two splicing effectors in a physiological context.
We have conﬁrmed the loss of a putative ESE motif
in SMN2 predicted by ESEﬁnder (Cartegni et al. 2003),
using a very different ESE-prediction program, RES-
CUE-ESE (Fairbrother et al. 2004). However, the pres-
ence of a bona ﬁde hnRNP A1 ESS motif in SMN2
remains uncertain. Two methods to identify ESS ele-
ments (Wang et al. 2004; Zhang and Chasin 2004) do
not predict the creation of a silencer by the c6t transition
(data not shown). Kashima and Manley (2003) com-
pared the sequence of SMN2 with known or putative
hnRNP A1–dependent ESSs from four genes. They noted
that the sequence of SMN2 exon 7 at positions 6–11 is
identical to CD44 (Entrez Gene accession number 960)
exon v5 at positions 4–9 and that both have some re-
semblance to the hnRNP A1 SELEX motif (Burd and
Dreyfuss 1994). In CD44, several linker-scan mutants
throughout the entire exon v5, including one that over-
laps the UAGACA sequence, result in higher levels of
exon v5 inclusion (Ko¨nig et al. 1998). Later, it was
shown that the activity of a dispersed silencer within
exon v5 is controlled by hnRNP A1, but this ESS appears
to be a composite of multiple elements located in sub-
domains throughout the exon, and no speciﬁc high-af-
ﬁnity binding site could be identiﬁed (Matter et al.
2000). Therefore, we cannot infer that positions 4–9 in
CD44 exon v5 and, by analogy, positions 6–11 in SMN2
deﬁne an hnRNP A1–binding site, especially considering
that this particular sequence fails to inhibit splicingwhen
analyzed in a heterologous context (Kashima and Man-
ley 2003). Similar to the situation in CD44 exon v5, we
found that hnRNP A1 plays a role in SMN2 exon 7
skipping but does so in a general manner, perhaps de-
pendent on other exon features or on the surrounding
intronic regions rather than on the proposed hnRNP A1
motif.
In contrast to the general inhibitory effect of hnRNP
A1 on CD44 and SMN2 splicing, bona ﬁde examples
of hnRNP A1–speciﬁc ESS elements have been identiﬁed
(Cartegni et al. 2002). One such element, ESS3, is found
in HIV-1 tat exon 3 (Amendt et al. 1995; Staffa and
Cochrane 1995; Si et al. 1998; Tange et al. 2001; Zhu
et al. 2001; Damgaard et al. 2002; Marchand et al.
2002). ESS3 comprises the sequence UAGUGA, which
matches the high-afﬁnity hnRNP A1–binding hexamer
at ﬁve positions. This motif is required for direct inter-
action with hnRNP A1 (Zhu et al. 2001) and for hnRNP
A1–mediated inhibition of splicing in vivo (Staffa and
Cochrane 1995) and in vitro (Si et al. 1998; Zhu et al.
2001; Damgaard et al. 2002). One of the SMN2 ex-
on 7 mutants tested by Kashima and Manley (2003),
SMN2-TG, introduces a sequence identical to the tat
ESS3 motif. Despite the fact that this mutation creates
a nearly perfect match to an hnRNP A1–binding site
that is a proven hnRNP A1–dependent ESS in its original
context, those authors reported that this mutation res-
cues exon 7 inclusion. When we analyzed an equivalent
mutant, SMN2.9t10g (ﬁg. 1), we found that this mu-
tation resulted in exon 7 skipping, a ﬁnding consistent
with the introduction of a genuine hnRNP A1–mediated
silencer element in this case and also with the concom-
itant disruption of the SF2/ASF motif.
The most compelling previous evidence supporting a
direct role for hnRNP A1 in SMN2 exon 7 skipping was
the activation of exon 7 inclusion upon transient knock-
down of hnRNP A1/A2 proteins by siRNAs (Kashima
and Manley 2003). We conﬁrmed this result, but when
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Figure 6 Models for the effects of the SMN2 CrT transition
on exon 7 splicing. Multiple positive and negative determinants inﬂu-
ence SMN1 and SMN2 splicing. In SMN1 (A), efﬁcient splicing is
driven by the interactions of SF2/ASF with the ESE in the 6c region
and of other factors with a separate enhancer downstream. There may
also be an interplay between the various elements and additional,
perhaps redundant, factors (“SR?”) might be involved. In this strong
exon deﬁnition context, a possible hnRNP A1/A2 role and/or the ac-
tion of a putative repressor (“R?”), are not sufﬁcient to inhibit splicing.
The loss of the SF2/ASF–dependent ESE in SMN2 (B) allows a sec-
ondary, non–SMN2-speciﬁc inhibitory action of hnRNP A1/A2, pos-
sibly in collaboration with “R?”. Positive interactions downstream
cannot counteract this inhibitory activity. Exon 7 inclusion in SMN2
can be rescued to SMN1-like levels by other means (white arrows),
such as reconstitution of the SF2/ASF–dependent ESE (or other ESEs)
(C), overexpression of some splicing activators (e.g., Tra2b1) (D),
down-regulation of hnRNP A1/A2 by RNAi (E), or the presence of
compounds that functionally replace SR proteins or ESEs (e.g., ES-
SENCE or TOES) (F). Fluctuations in different cells and tissues in the
relative levels of SF2/ASF, hnRNP A1/A2, and/or the additional splic-
ing factors involved would therefore determine the precise pattern of
SMN2 exon 7 splicing. Green boxes represent known ESEs. Red and
orange boxes represent putative ESS and ISS elements, respectively.
we included controls for speciﬁcity, using three different
mutants (SMN1.PyD, SMN.t3, and SMN.t4) that result
in exon 7 skipping without introducing an hnRNP A1
motif, we found that knocking down hnRNP A1/A2 led
to a comparable increase in exon 7 inclusion in all cases
(ﬁg. 3). We conclude that repression of exon 7 inclusion
by hnRNP A1/A2 is a generalized effect, independent of
the CrT transition. Thus, most of the results in the
Kashima and Manley (2003) report can be explained by
the general property of hnRNP A1 to promote skipping
of alternative exons (Mayeda et al. 1993), rather than
by an SMN2-speciﬁc effect.
On the basis of our present results and of previous
work, we propose a new model for SMN1 and SMN2
exon 7 splicing, which is depicted in ﬁgure 6. According
to this model, hnRNP A1 acts in a general manner to
block splicing of exon 7 in the absence of the dominant
SF2/ASF–dependent ESE (ﬁg. 6B). Consistent with the
known RNA-binding and repressor properties of hnRNP
A1 (Zhu et al. 2001; reviewed by Cartegni et al. [2002]),
its binding to SMN1 and SMN2 RNAs may nucleate
from as-yet-uncharacterized high-afﬁnity sites at some
distance from the ESE. The presence of the SF2/ASF–
dependent ESE in SMN1 supersedes this inhibition (ﬁg.
6A). The same is true when exon 7 deﬁnition in the
SMN2 context is strengthened by various means, such
as the reconstitution of a new ESE at a similar position
(ﬁg. 6C), the overexpression of proteins that bind to
other enhancer elements in exon 7 (ﬁg. 6D), the targeting
of synthetic molecules that mimic SR protein functions—
for example, ESSENCE (Cartegni and Krainer 2003) and
TOES (Skordis et al. 2003) (ﬁg. 6F)—or the reduction
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in the levels of inhibitory factors by siRNA treatment
(ﬁg. 6E).
Other splicing factors, such as Tra2b1, SRp30c, and
hnRNP G (UniProt accession numbers P62995-1,
Q13242, and P38159, respectively), have also been
shown to inﬂuence SMN1 and SMN2 exon 7 inclusion
via elements in the central portion of exon 7 (Hofmann
et al. 2000; Hofmann and Wirth 2002; Young et al.
2002), and additional regulatory elements, both in exon
7 (Singh et al. 2004a, 2004b) and in the ﬂanking introns
(Miyajima et al. 2002; Miyaso et al. 2003), appear to
be important for exon 7 recognition (ﬁg. 6). Because
SMN1 and SMN2 exon 7 sequences are identical, with
the exception of the CrT transition at position 6, reg-
ulatory sequences that do not encompass this position
are unlikely to be directly involved in the SMN2 exon
7 splicing defect. However, they clearly play an impor-
tant role in exon 7 splicing efﬁciency and may inﬂuence
the overall effect of the CrT transition.
It is possible that another repressor (“R?,” ﬁg. 6) dif-
ferent from hnRNP A1/A2 recognizes SMN2 sequences
with some degree of speciﬁcity. In support of this notion,
a recent study showed that, in the absence of the ESE,
several mutations in the ﬁrst 5 nt (GGTTT) of SMN2
exon 7 partially rescue splicing (Singh et al. 2004a), and
this motif is also present in 11 of 141 recently described
ESS decamer elements (Wang et al. 2004). However, this
putative ESS at the beginning of the exon is not sufﬁcient
to overcome the effect of the SF2/ASF ESE (ﬁg. 1 and
table 1). Consistent with this ﬁnding, our reanalysis of
the extensive mutational and iterative selection data of
Singh and colleagues (2004a, 2004b) shows a good cor-
relation between exon 7 inclusion and the presence of
an SF2/ASF ESE motif (ﬁg. A3 [online only]). In partic-
ular, in the functional SELEX data obtained by random-
ization of the ﬁrst 6 nt of exon 7 (Singh et al. 2004a),
SF2/ASF–dependent ESE motifs are present in 33 of the
42 selected clones (ﬁg. A3 [online only]). Likewise, par-
tial randomization of the entire exon (Singh et al. 2004b)
resulted in high-score SF2/ASF motifs at the original po-
sition (6–12) in 25 of the 59 selected exons and in 40
of the 59 exons when partial overlaps with the original
position were considered (data not shown). Because only
∼4% of all possible 16,384 heptamers represent high-
score SF2/ASF motifs (Wang et al. 2005), it is clear that
these motifs are greatly enriched among sequences se-
lected for their ability to promote exon 7 inclusion, thus
strongly reinforcing the notion that the SF2/ASF–depen-
dent ESE is the primary splicing determinant in this re-
gion and that the activity from any putative inhibitory
sites is secondary to the loss of the ESE.
Previous negative results from in vivo SF2/ASF–de-
pletion experiments suggested that SF2/ASF is not
strictly required for exon 7 inclusion in SMN1. The de-
pletion of SF2/ASF from cells, either genetically in the
chicken cell line DT-40 (Kashima and Manley 2003) or
by use of siRNA-mediated knockdown in HeLa cells (L.
Cartegni, M. L. Hastings, J. A. Calarco, E. de Stanchino,
and A. R. Krainer, unpublished data), has little effect on
SMN1 splicing. Although a decrease in SMN1 exon 7
inclusion in the absence of SF2/ASF is a logical expec-
tation, there are several possible alternative explanations
for the lack of such an effect. First, SF2/ASF, which is a
general splicing factor, may be important for both exon
8 and exon 7 splicing. There are six high-score SF2/ASF
motifs in exon 8 (data not shown) and, if any of them
represent genuine ESEs, the depletion of SF2/ASF may
equalize the competition between the 3′ splice sites pre-
ceding these two exons, thereby resulting in no effect
(or even in a positive effect) on overall exon 7 inclusion.
Indeed, blocking the 3′ splice site of exon 8 with anti-
sense oligonucleotides increases the extent of exon 7 in-
clusion (Lim and Hertel 2001). Second, because the de-
pletion of SF2/ASF compromises DT-40 cell viability
(Wang et al. 1996), this approach may not provide a
direct indication of normal SF2/ASF activity, since sec-
ondary effects associated with cellular stress and apo-
ptosis are likely in play. Third, SR proteins are well
known to have partially redundant functions (reviewed
by Cartegni et al. [2002]). As previously suggested (Car-
tegni and Krainer 2002), additional SR protein(s) may
recognize the ESE in the absence of SF2/ASF and sub-
stitute for it in ESE-dependent exon 7 splicing, so that
a double depletion might be required to observe an ef-
fect. By analogy, in the case of hnRNP A1, the simul-
taneous depletion of the related protein hnRNP A2 is
required to observe a strong effect on SMN2 exon 7
inclusion (ﬁg. 3a) (Kashima and Manley 2003). Fourth,
compensatory mechanisms might also be triggered or
enhanced through auto- and cross-regulatory loops in-
volving different splicing factors and their respective al-
ternative splicing isoforms; many examples of such reg-
ulatory loops have been described elsewhere (reviewed
by Bourgeois et al. [2004]). Thus, a reduction in the
levels of SF2/ASF could directly or indirectly lead to
changes in the levels of other splicing factors, which
would, in turn, maintain efﬁcient SMN1 exon 7
inclusion.
Any of these scenarios, or a combination of them,
could account for the absence of an apparent effect of
SF2/ASF depletion on SMN2 splicing. On the other
hand, there is substantial evidence supporting a direct
role for SF2/ASF in SMN1 exon 7 splicing. Mutational
analysis shows a strong correlation between exon 7 in-
clusion and the presence of an ESE-dependent SF2/ASF
motif (ﬁg. 1), which also enhances splicing in a heter-
ologous context (Cartegni and Krainer 2002). SF2/ASF
preferentially interacts with SMN1 compared with
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SMN2 transcripts (ﬁg. 2) and makes direct contact with
the ESE site (Cartegni and Krainer 2002). SF2/ASF ov-
erexpression can promote SMN1 exon 7 inclusion in a
weakened context that preserves the ESE (ﬁg. 3D), and
SF2/ASF, but not another SR protein, SC35, speciﬁcally
activates SMN1 exon 7 splicing in an in vitro S100-
complementation assay (Cartegni and Krainer 2002). As
is the case for many genes (reviewed by Cartegni et al.
[2002] and Black [2003]), SF2/ASF–dependent splicing
is counteracted by hnRNPA1/A2 in an antagonistic re-
lationship that is likely physiologically relevant for the
modulation of SMN splicing as well.
Our results from overexpression of hnRNP A1 (ﬁg.
4) indicate that changes in the cellular levels of hnRNP
A1 can modulate the extent of exon 7 inclusion in both
SMN1 and SMN2. Likewise, SF2/ASF overexpression
experiments (ﬁg. 3D) showed that exon 7 inclusion is
sensitive to the cellular levels of SF2/ASF. These results
suggest that exon 7 inclusion is determined in part by
the cellular levels of these two proteins, which have op-
posite effects on splicing. The balance between SF2/ASF
and hnRNP A1 activity in exon 7 inclusion appears to
hinge upon the recognition of the ESE in exon 7 by SF2/
ASF, as inactivation of this ESE in SMN2 results in the
substantial loss of exon 7 inclusion. This hypothesis pre-
dicts that, in the absence of hnRNP A1, the ESE should
become dispensable for the splicing of exon 7, which is,
indeed, the case (ﬁgs. 3 and 5). Because we ﬁnd no evi-
dence that hnRNP A1 is acting via a speciﬁc binding site
created in SMN2, we presume that hnRNP A1 inhibition
of exon 7 splicing is mediated by as-yet-undetermined
splicing silencer sequences. Putative high-afﬁnity binding
sites in and around exon 7, calculated with a newly
derived hnRNP A1 matrix, are shown in appendix A
(ﬁgs. A1 and A5 [online only]).
The reason why SMN1 gene disruption causes the
selective degeneration of spinal cord motor neurons
without affecting other tissues is not known. A threshold
level of SMN protein is essential for cell viability (re-
viewed by Frugier et al. [2002]) and, clearly, the low
level of full-length transcripts produced from SMN2 is
sufﬁcient for the survival of most cell types in patients
with SMA and mouse models. It is possible that motor
neurons have a greater need for the SMN protein or that
SMN performs additional, neuron-speciﬁc functions (re-
viewed by Sendtner [2001] and Gubitz et al. [2004]).
Alternatively, SMN2 may produce less functional SMN
protein in spinal motor neurons compared with other
cells, which would only be detrimental in affected SMA
individuals (Coovert et al. 1997). One intriguing pos-
sibility is that a-motor neurons express high levels of
hnRNP A/B proteins and/or low levels of SF2/ASF or
other relevant splicing factors, resulting in increased
skipping of SMN2 exon 7. Although there is no direct
evidence that this is, in fact, the case for motor neurons
and SMA, the relative levels of hnRNP A1/A2, SF2/ASF,
and other SR proteins do vary with cell type and de-
velopmental stage (Hanamura et al. 1998; reviewed by
Dreyfuss et al. [2002]), and our results demonstrate that
SF2/ASF and hnRNP A1 levels can determine the extent
of exon 7 splicing.
Any treatment that improves the ratio of SMN full-
length to SMND7 from SMN2 might have therapeutic
value, but targeting splicing factors could be problem-
atic. For example, hnRNP A1 could be viewed as a pos-
sible therapeutic target, given its inhibitory effect on
SMN2 exon 7 splicing (Kashima and Manley 2003).
However, in light of its properties as a global splicing
inhibitor and its involvement in many other cellular pro-
cesses (reviewed by Dreyfuss et al. [2002]), targeting
hnRNP A1 could lead to undesirable effects. Likewise,
most SR proteins probably regulate the alternative splic-
ing of numerous genes, and it may be difﬁcult to identify
small molecules that modulate their effects with a high
degree of speciﬁcity and/or without associated toxicity.
Nevertheless, drugs with even limited speciﬁcity could
provide a favorable risk/beneﬁt ratio, especially consid-
ering the severity of SMA and some of the other dis-
orders associated with defective splicing. The recent
identiﬁcation of small-molecule inhibitors speciﬁc for in-
dividual SR proteins provided the ﬁrst indication that
this family of proteins can be targeted pharmacologically
(Soret et al. 2005). Gene-speciﬁc strategies that rely on
antisense base pairing to increase SMN2 exon 7 inclu-
sion provide an intrinsically higher degree of speciﬁcity,
although they face their own unique obstacles.
Mutations in cis-elements that result in splicing alter-
ations are commonly observed (reviewed by Ca´ceres and
Kornblihtt [2002], Faustino and Cooper [2003], and Pa-
gani and Baralle [2004]). However, how such mutations
exert their effects is not always obvious. Because cis-
acting mutations that affect splicing may result in gain
of function (e.g., creation of an ESE or ESS element),
loss of function (e.g., destruction of an ESE or ESS el-
ement), or even a combination of both, in addition to
potential alterations in RNA secondary structure (re-
viewed by Buratti and Baralle [2004]), a wide variety of
approaches should be employed, whenever possible, to
elucidate the underlying mechanisms.
Our ﬁndings demonstrate the complexity of the re-
lationship between positive and negative splicing ele-
ments and the factors that recognize them, and they
underscore the importance of exon identity determinants
for both constitutive and alternative splicing. The results
also illustrate the need for a thorough understanding of
splicing mechanisms, to facilitate accurate phenotypic
risk assessment, and for the development of effective
therapeutic treatments for human genetic diseases.
76 The American Journal of Human Genetics Volume 78 January 2006 www.ajhg.org
Acknowledgments
We thank Ravi Sachidanandam for helpful advice on sta-
tistical tests. This work was supported by National Institutes
of Health grant NS041621 (to A.R.K.). L.C. is supported by
the W. Hearst Foundation.
Web Resources
Accession numbers and URLs for data presented herein are as
follows:
Entrez Gene, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dbpgene/
(for SMN1, SMN2, and CD44)
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